Norovirus in healthcare settings

Current Opinion in Infectious Diseases

Volumn 27, Issue 5, 2014, Pages 437-443

  Iturriza Gómara, Miren ^a   Lopman, Benjamin ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

hospital; norovirus; risk factors; transmission

Indexed keywords

ANTIVIRUS AGENT; HOST FACTOR; VIRUS VACCINE; CORTICOSTEROID;

ANTIVIRAL THERAPY; ENVIRONMENT; HEALTH CARE; HEALTH CARE ENVIRONMENT; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); VIRUS TRANSMISSION; CALICIVIRIDAE INFECTIONS; CROSS INFECTION; DISEASE OUTBREAKS; ECONOMICS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HOSPITAL; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; NURSING HOME; NUTRITIONAL STATUS; ORGANIZATION AND MANAGEMENT; PATHOGENICITY; PHYLOGENY; PROCEDURES; RISK FACTOR; TRANSMISSION;

ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; CALICIVIRIDAE INFECTIONS; CROSS INFECTION; DISEASE OUTBREAKS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOSPITALS; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION CONTROL; MOLECULAR SEQUENCE DATA; NOROVIRUS; NURSING HOMES; NUTRITIONAL STATUS; PHYLOGENY; RISK FACTORS;

EID: 84906936747     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000094     Document Type: Review

References (77)

1. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198-1205.
2. Tam CC, Rodrigues LC, Viviani L, et al. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut 2012; 61:69-77.
3. Gastanaduy PA, Hall AJ, Curns AT, et al. Burden of norovirus gastroenteritis in the ambulatory setting-United States, 2001-2009. J Infect Dis 2013; 207:1058-1065.
4. Lopman BA, Reacher MH, Vipond IB, et al. Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002-2003. Emerg Infect Dis 2004; 10:1827-1834.
5. Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121-1130.
6. Harris JP, Adams NL, Lopman BA, et al. The development of web-based surveillance provides new insights into the burden of norovirus outbreaks in hospitals in England. Epidemiol Infect 2014; 142:1590-1598.
7. Zanini B, Ricci C, Bandera F, et al. Incidence of postinfectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107:891-899.
8. Porter CK, Faix DJ, Shiau D, et al. Postinfectious gastrointestinal disorders following norovirus outbreaks. Clin Infect Dis 2012; 55:915-922.
9. Harris JP, Edmunds WJ, Pebody R, et al. Deaths from norovirus among the elderly, England and Wales. Emerg Infect Dis 2008; 14:1546-1552.
10. Gustavsson L, Andersson LM, Lindh M, Westin J. Excess mortality following community-onset norovirus enteritis in the elderly. J Hosp Infect 2011; 79:27-31.
11. Rondy M, Koopmans M, Rotsaert C, et al. Norovirus disease associated with excess mortality and use of statins: a retrospective cohort study of an outbreak following a pilgrimage to Lourdes. Epidemiol Infect 2011; 139:453-463.
12. Frange P, Touzot F, Debre M, et al. Prevalence and clinical impact of norovirus fecal shedding in children with inherited immune deficiencies. J Infect Dis 2012; 206:1269-1274.
13. Haessler S, Granowitz EV. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med 2013; 368:971.
14. Munir N, Liu P, Gastanaduy P, et al. Norovirus infection in immunocompromised children and children with hospital-acquired acute gastroenteritis. J Med Virol 2014; 86:1203-1209.
15. Sukhrie FH, Siebenga JJ, Beersma MF, Koopmans M. Chronic shedders as reservoir for nosocomial transmission of norovirus. J Clin Microbiol 2010; 48:4303-4305.
16. Wingfield T, Gallimore CI, Xerry J, et al. Chronic norovirus infection in an HIVpositive patient with persistent diarrhoea: a novel cause. J Clin Virol 2010; 49:219-222.
17. Harris JP, Lopman BA, O'Brien SJ. Infection control measures for norovirus: a systematic review of outbreaks in semi-enclosed settings. J Hosp Infect 2010; 74:1-9.
18. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control. 2011; 60(RR-3):1-18. Epub 2011/03/04.
19. MacCannell T, Umscheid CA, Agarwal RK, et al. Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infect Control Hosp Epidemiol 2011; 32:939-969.
20. Harris JP, Adak GK, O'Brien SJ. To close or not to close Analysis of 4 year's data from national surveillance of norovirus outbreaks in hospitals in England. BMJ Open 2014; 4:e003919.
21. Temime L, Opatowski L, Pannet Y, et al. Peripatetic health-care workers as potential superspreaders. Proc Natl Acad Sci USA2009; 106:18420-18425.
22. Harris JP, Lopman BA, Cooper BS, O'Brien SJ. Does spatial proximity drive norovirus transmission during outbreaks in hospitals BMJ Open 2013; 3:e003060.
23. Loveridge P, Cooper D, Elliot AJ, et al. Vomiting calls to NHS direct provide an early warning of norovirus outbreaks in hospitals. J Hosp Infect 2010; 74:385-393.
24. Ahmed SM, Lopman BA, Levy K. A systematic review and meta-analysis of the global seasonality of norovirus. PLoS One 2013; 8:e75922.
25. Green K. Caliciviridae: the noroviruses. In: Knipe DM, Howley PM, editors. Fields virology, 6th ed. Philadelphia: Lippincott Williams Wilkins; 2013.
26. Desai R, Hembree CD, Handel A, et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin Infect Dis 2012; 55:189-193.
27. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol 2010; 8:231-241.
28. Debbink K, Lindesmith LC, Donaldson EF, Baric RS. Norovirus immunity and the great escape. PLoS Pathog 2012; 8:e1002921.
29. Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012; 8:e1002705.
30. Lindesmith LC, Costantini V, Swanstrom J, et al. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 2013; 87:2803-2813.
31. Debbink K, Lindesmith LC, Donaldson EF, et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis 2013; 208:1877-1887.
32. Evans MR, Meldrum R, Lane W, et al. An outbreak of viral gastroenteritis following environmental contamination at a concert hall. Epidemiol Infect 2002; 129:355-360.
33. Sawyer LA, Murphy JJ, Kaplan JE, et al. 25-to 30-nm virus particle associated with a hospital outbreak of acute gastroenteritis with evidence for airborne transmission. Am J Epidemiol 1988; 127:1261-1271.
34. Nenonen NP, Hannoun C, Svensson L, et al. Norovirus GII.4 detection in environmental samples from patient rooms during nosocomial outbreaks. J Clin Microbiol 2014; 52:2352-2358.
35. Lai CC, Wang YH, Wu CY, et al. A norovirus outbreak in a nursing home: norovirus shedding time associated with age. J Clin Virol 2013; 56:96-101.
36. Boxman IL, Dijkman R, te Loeke NA, et al. Environmental swabs as a tool in norovirus outbreak investigation, including outbreaks on cruise ships. J Food Prot 2009; 72:111-119.
37. Lopman B, Gastanaduy P, Park GW, et al. Environmental transmission of norovirus gastroenteritis. Curr Opin Virol 2012; 2:96-102.
38. Lee RM, Lessler J, Lee RA, et al. Incubation periods of viral gastroenteritis: a systematic review. BMC Infect Dis 2013; 13:446.
39. Atmar RL, Opekun AR, Gilger MA, et al. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis 2014; 209:1016-1022.
40. Sukhrie FH, Teunis P, Vennema H, et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis 2012; 54:931-937.
41. Teunis P, Heijne JC, Sukhrie F, et al. Infectious disease transmission as a forensic problem: who infected whom J R Soc Interface 2013; 10:20120955.
42. Hall AJ, Wikswo ME, Manikonda K, et al. Acute gastroenteritis surveillance through the national outbreak reporting system, United States. Emerg Infect Dis 2013; 19:1305-1309.
43. Rhinehart E, Walker S, Murphy D, et al. Frequency of outbreak investigations in US hospitals: results of a national survey of infection preventionists. Am J Infect Control 2012; 40:2-8.
44. Health Protection Agency, British Infection Association, Healthcare Infection Society, Infection Prevention Society, National Concern for Healthcare Infections, National Health Service Confederation. Guidelines for the management of norovirus outbreaks in acute and community health and social care settings. 2012.
45. Ireland NDSC. National guidelines on the management of outbreaks of norovirus infection in healthcare settings. https://www.hpsc.ie/hpsc/A-Z/ Gastroenteric/ViralGastroenteritis/Publications/File,1194,en.pdf2004.
46. Australia CDN. Guidelines for the public health management of gastroenteritis outbreaks due to norovirus or suspected viral agents in Australia. https://www.health.gov.au/internet/main/publishing.nsf/Content/cda- cdna-norovirus. htm/$File/norovirus-guidelines.pdf2010.
47. Park GW, Barclay L, Macinga D, et al. Comparative efficacy of seven hand sanitizers against murine norovirus, feline calicivirus, and GII. J Food Prot 2010; 73:2232-2238.
48. Blaney DD, Daly ER, Kirkland KB, et al. Use of alcohol-based hand sanitizers as a risk factor for norovirus outbreaks in long-term care facilities in northern New England: December 2006 to March. Am J Infect Control 2011; 39:296-301.
49. Tan M, Jiang X. Norovirus-host interaction: implications for disease control and prevention. Expert Rev Mol Med 2007; 9:1-22.
50. Tan M, Jiang X. Histo-blood group antigens: a common niche for norovirus and rotavirus. Expert Rev Mol Med 2014; 16:e5.
51. Zhu S, Regev D, Watanabe M, et al. Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains. PLoS Pathog 2013; 9:e1003592.
52. Chen L, Wu D, Ji L, et al. Bioinformatics analysis of the epitope regions for norovirus capsid protein. BMC Bioinformatics 2013; 14 (Suppl 4):S5.
53. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol 2012; 86:1214-1226.
54. Debbink K, Lindesmith LC, Donaldson EF, et al. Chimeric GII.4 norovirus virus-like particle based vaccines induce broadly blocking immune responses. J Virol 2014; 88:7256-7266.
55. Bull RA, White PA. Mechanisms of GII.4 norovirus evolution. Trends Microbiol 2011; 19:233-240.
56. Kaufman SS, Green KY, Korba BE. Treatment of norovirus infections: moving antivirals from the bench to the bedside. Antiviral Res 2014; 105:80-91.
57. Debbink K, Lindesmith LC, Ferris MT, et al. Within host evolution results in antigenically distinct GII.4 noroviruses. J Virology 2014; 88:7244-7255.
58. Phillips G, Tam CC, Conti S, et al. Community incidence of norovirusassociated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol 2010; 171:1014-1022.
59. Fulop T, Pawelec G, Castle S, Loeb M. Immunosenescence and vaccination in nursing home residents. Clin Infect Dis 2009; 48:443-448.
60. Mabbott NA, Kobayashi A, Sehgal A, et al. Aging and the mucosal immune system in the intestine. Biogerontology 2014. DOI: 10.1007/s10522-014-9498-z. [Epub ahead of print]
61. Bui T, Kocher J, Li Y, et al. Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J Gen Virol 2013; 94 (Pt 9):2005-2016.
62. Jung K, Wang Q, Kim Y, et al. The effects of simvastatin or interferon-alpha on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. PLoS One 2012; 7:e41619.
63. Miura T, Sano D, Suenaga A, et al. Histo-blood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses. J Virol 2013; 87:9441-9451.
64. Nelson AM, Walk ST, Taube S, et al. Disruption of the human gut microbiota following norovirus infection. PLoS One 2012; 7:e48224.
65. Hopkins MJ, Sharp R, Macfarlane GT. Variation in human intestinal microbiota with age. Dig Liver Dis 2002; 34 (Suppl 2):S12-S18.
66. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488:178-184.
67. Kuss SK, Best GT, Etheredge CA, et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 2011; 334:249-252.
68. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435-438.
69. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 2011; 45:S159-S167.
70. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108:1367.
71. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012; 8:e1002995.
72. Yazawa S, Yokobori T, Ueta G, et al. Blood group substances as potential therapeutic agents for the prevention and treatment of infection with noroviruses proving novel binding patterns in human tissues. PLoS One 2014; 9:e89071.
73. Arias A, Emmott E, Vashist S, Goodfellow I. Progress towards the prevention and treatment of norovirus infections. Future Microbiol 2013; 8:1475-1487.
74. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365:2178-2187.
75. LoBue AD, Lindesmith L, Yount B, et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006; 24:5220-5234.
76. Tamminen K, Lappalainen S, Huhti L, et al. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013; 8:e70409.
77. Parra GI, Bok K, Taylor R, et al. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012; 30:3580-3586.